Targeted Therapies in Advanced Cutaneous Squamous Cell Carcinoma

Cosibelimab is now FDA approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma that is not eligible for curative surgery or radiation.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the 2024 update to the RELATIVITY-047 trial in advanced melanoma in the first article of a 2-part series.

During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants look at benefits of nivolumab combinations for brain metastases and PD-L1 positivity in the metastatic melanoma population in the second article of a 2-part series.

The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.